Doctor of Osteopathy Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Julia Ronecker

Child & Adolescent Psychiatry Crestview Hills, KY Doctor of Osteopathy

NPI 1568966042 CMS profile 11461996

334 Thomas More Pkwy, Crestview Hills, KY 41017

Open in the dashboard

General payments

$2,117

123 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julia Ronecker of Crestview Hills, KY is reported in the CMS Open Payments database as having received $2,117 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,138 63
2024 General $741 48
2023 General $238 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julia Ronecker
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Julia Ronecker were reported at $1,138. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Julia Ronecker Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $0 $124 $40–$382 $149
2023 $238 $130 $45–$420 $160
2024 $741 $141 $42–$490 $164
2025 $1,138 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. ITI, Inc. $325 25 payments
  2. Otsuka America Pharmaceutical, Inc. $296 21 payments
  3. Lundbeck LLC $254 13 payments
  4. Alkermes, Inc. $253 10 payments
  5. Janssen Pharmaceuticals, Inc $165 8 payments
  6. Corium, Inc. $107 7 payments
  7. Teva Pharmaceuticals USA, Inc. $95 5 payments
  8. Supernus Pharmaceuticals, Inc. $81 5 payments
  9. Neurocrine Biosciences, Inc. $75 4 payments
  10. Almatica Pharma LLC $67 3 payments
  11. Other $400 22 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,117 123 payments
Products named General payments · program years 2023–2025
  1. LYBALVI $253 10 payments
  2. ARISTADA Cns $253 10 payments
  3. ARISTADA Cns $253 10 payments
  4. ARISTADA Cns $253 10 payments
  5. ARISTADA Cns $253 10 payments
  6. ABILIFY MAINTENA $241 14 payments
  7. CAPLYTA $234 21 payments
  8. REXULTI Psychiatry $171 12 payments
  9. REXULTI Psychiatry $151 9 payments
  10. INVEGA SUSTENNA $127 6 payments
  11. Other $1,185 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$5,537

Medicare's payments for the services billed

Medicare patients

26

Average age 72

Services billed

72

11 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 69%
Depression 65%
Arthritis 54%
Ischemic heart disease 50%
Chronic kidney disease 50%
Atrial fibrillation 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $206
$206 — —
REXULTI
  • Lundbeck LLC $90
  • Otsuka America Pharmaceutical, Inc. $56
$146 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $67
$67 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $54
$54 — —
Azstarys
  • Corium, Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record